​​Effectiveness of mRESVIA Against Serious Endpoints related to RSV in Kaiser Permanente Northern California (ERASE-RSV)​

Study identification

• EU PAS number:
  EUPAS1000000946
• Study ID:
  1000000946
• Official title and acronym:
  ​​Effectiveness of mRESVIA Against Serious Endpoints related to RSV in Kaiser Permanente Northern California (ERASE-RSV)​
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual:30/10/2024

Study start date

Actual:01/03/2026

Date of final study report

Planned:31/01/2029

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only

Other study registration identification numbers and links

mRNA-1345-P919